Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria

Molecular Immunology

Volumn 54, Issue 1, 2013, Pages 58-67

  Ryden, Patrik ^b   Twine, Susan ^a   Shen, Hua ^a   Harris, Gregory ^a   Chen, Wangxue ^a   Sjostedt, Anders ^b   Conlan, Wayne ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Antibodies; Chemokines; Cytokines; Francisella; Mutants

Indexed keywords

CYTOKINE; FRANCISELLA TULARENSIS VACCINE; GAMMA INTERFERON; LIVE VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; DRUG MECHANISM; FEMALE; FRANCISELLA TULARENSIS; GENE DELETION; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INHALATION; ANIMALS; BACTERIAL VACCINES; FEMALE; FRANCISELLA TULARENSIS; GENE DELETION; IMMUNITY; IMMUNITY, INNATE; MICE; MICE, INBRED BALB C; ORGANISMS, GENETICALLY MODIFIED; TULAREMIA; VACCINATION; VIRULENCE;

BACTERIA (MICROORGANISMS); FRANCISELLA; FRANCISELLA TULARENSIS; MUS;

EID: 84869879671     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.10.043     Document Type: Article

References (34)

1. Acosta-Rodriguez E.V., Napolotani G., Lanzavecchia A., Sallustro F. Interleukin 1β and 6, but not transforming growth factor-β are essential for the differentiation of interleukin-17 producing human T helper cells. Nature Immunology 2007, 8:942-949.
2. Barrett A.D., Beasley D.W. Development pathway for biodefense vaccines. Vaccine 2009, 27(Suppl. 4):D2-D7.
3. Burke D.S. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. Journal of Infectious Diseases 1977, 135:55-60.
4. Conlan J.W. Tularemia vaccines: recent developments and remaining hurdles. Future Microbiology 2011, 6:391-405.
5. Conlan J.W., Shen H., Golovliov I., Zingmark C., Oyston P.C., Chen W., House R.V., Sjostedt A. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine 2010, 28:1824-1831.
6. De Pascalis R., Chou A.Y., Bosio C.M., Huang C.Y., Follmann D.A., Elkins K.L. Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS. PLoS Pathogens 2012, 8:e1002494.
7. Dennis D.T., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Friedlander A.M., Hauer J., Layton M., Lillibridge S.R., McDade J.E., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Tonat K. Tularemia as a biological weapon: medical and public health management. Journal of the American Medical Association 2001, 285:2763-2773.
8. Derrick S.C., Yabe I.M., Yang A., Morris S.L. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011, 29:2902-2909.
9. Eigelsbach H.T., Downs C.M. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. Journal of Immunology 1961, 87:415-425.
10. Eigelsbach H.T., Tulis J.J., Overholt E.L., Griffith W.R. Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine. Proceedings of the Society for Experimental Biology and Medicine 1961, 108:732-734.
11. Elkins K.L., Cowley S.C., Bosio C.M. Innate and adaptive immunity to Francisella. Annals of the New York Academy of Sciences 2007, 1105:284-324.
12. Eneslatt K., Normark M., Bjork R., Rietz C., Zingmark C., Wolfraim L.A., Stoven S., Sjostedt A. Signatures of T cells as correlates of immunity to Francisella tularensis. PLoS ONE 2012, 7:e32367.
13. Eneslatt K., Rietz C., Ryden P., Stoven S., House R.V., Wolfraim L.A., Tarnvik A., Sjostedt A. Persistence of cell-mediated immunity three decades after vaccination with the live vaccine strain of Francisella tularensis. European Journal of Immunology 2011, 41:974-980.
14. Golovliov I., Sjostedt A., Mokrievich A., Pavlov V. A method for allelic replacement in Francisella tularensis. FEMS Microbiology Letters 2003, 222:273-280.
15. Horne A.D., Clifford J., Goldenthal K.L., Kleppinger C., Lachenbruch P.A. Preventive vaccines against bioterrorism: evaluation of efficacy and safety. Vaccine 2004, 23:84-90.
16. Hornick R.B., Eigelsbach H.T. Aerogenic immunization of man with live tularemia vaccine. Bacteriological Reviews 1966, 30:532-538.
17. Kadzhaev K., Zingmark C., Golovliov I., Bolanowski M., Shen H., Conlan W., Sjostedt A. Identification of genes contributing to the virulence of Francisella tularensis SCHU S4 in a mouse intradermal infection model. PLoS ONE 2009, 4:e5463.
18. Lindemann S.R., Peng K., Long M.E., Hunt J.R., Apicella M.A., Monack D.M., Allen L.A., Jones B.D. Francisella tularensis Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages. Infection and Immunity 2011, 79:581-594.
19. Luster A.D. The role of chemokines in linking innate and adaptive immunity. Current Opinion in Immunology 2002, 14:129-135.
20. McCrumb F.R. Aerosol infection of man with Pasteurella tularensis. Bacteriological Reviews 1961, 25:262-267.
21. Meibom K.L., Dubail I., Dupuis M., Barel M., Lenco J., Stulik J., Golovliov I., Sjostedt A., Charbit A. The heat-shock protein ClpB of Francisella tularensis is involved in stress tolerance and is required for multiplication in target organs of infected mice. Molecular Microbiology 2008, 67:1384-1401.
22. Oyston P.C. Francisella tularensis vaccines. Vaccine 2009, 27(Suppl. 4):D48-D51.
23. Paranavitana C., Zelazowska E., DaSilva L., Pittman P.R., Nikolich M. Th17 cytokines in recall responses against Francisella tularensis in humans. Journal of Interferon and Cytokine Research 2010, 30:471-476.
24. Rockx-Brouwer D., Chong A., Wehrly T.D., Child R., Crane D.D., Celli J., Bosio C.M. Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. PLoS ONE 2012, 7:e37752.
25. Saslaw S., Eigelsbach H.T., Prior J.A., Wilson H.E., Carhart S. Tularemia vaccine study. II. Respiratory challenge. Archives of Internal Medicine 1961, 107:702-714.
26. Saslaw S., Eigelsbach H.T., Wilson H.E., Prior J.A., Carhart S. Tularemia vaccine study. I. Intracutaneous challenge. Archives of Internal Medicine 1961, 107:689-701.
27. Scheerlink J-P.Y. Genetic adjuvants for DNA vaccines. Vaccine 2001, 19:2647-2656.
28. Shen H., Harris G., Chen W., Sjostedt A., Ryden P., Conlan W. Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS ONE 2010, 5:e13349.
29. Sjostedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Annals of the New York Academy of Sciences 2007, 1105:1-29.
30. Twine S., Bystrom M., Chen W., Forsman M., Golovliov I., Johansson A., Kelly J., Lindgren H., Svensson K., Zingmark C., Conlan W., Sjostedt A. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infection and Immunity 2005, 73:8345-8352.
31. Twine S., Shen H., Harris G., Chen W., Sjostedt A., Ryden P., Conlan W. BALB/c mice, but not C57BL/6 mice immunized with a DeltaclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses. Vaccine 2012, 30:3634-3645.
32. Twine S.M., Mykytczuk N.C., Petit M., Tremblay T.L., Lanthier P., Conlan J.W., Kelly J.F. Francisella tularensis proteome: low levels of ASB-14 facilitate the visualization of membrane proteins in total protein extracts. Journal of Proteome Research 2005, 4:1848-1854.
33. Twine S.M., Petit M.D., Fulton K.M., House R.V., Conlan J.W. Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS). PLoS ONE 2010, 5:e10000.
34. Williamson E.D., Duchars M.G., Kohberger R. Predictive models and correlates of protection for testing biodefence vaccines. Expert Review of Vaccines 2010, 9:527-537.